MedTrace Logo

Bone Health Observational Study

NCT00632905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 599

Last updated 2017-09-28

No results posted yet for this study

Summary

Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced Bone Loss(CTIBL) in their patients. The gold standard for evaluating BMD is dual energy x-ray absorptiometry (DEXA). The proposed study will provide some of the first prospective data on the rates of Skeletal Related Events (SREs) in prostate cancer patients undergoing ADT and help develop official guidelines on the use of DEXA screening for prostate cancer patients.

Conditions

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • CMX Research

    lead OTHER

Principal Investigators

  • Richard W Casey, M.D. · CMX Research

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632905 on ClinicalTrials.gov